Endocrinologia Diabetes Y Nutricion最新文献

英文中文

Prevalence of chronic kidney disease in patients treated in Endocrinology, Diabetes and Nutrition outpatient clinics: A single-center, cross-sectional, retrospective, descriptive study 在内分泌、糖尿病和营养门诊治疗的患者中慢性肾病的患病率：一项单中心、横断面、回顾性、描述性研究

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-07-30 DOI: 10.1016/j.endien.2025.501612

Noel Roig-Marín , Javier Torres Hernández , Cristina Delicado Hernández , Laura Navarro Casado , Pedro J. Pinés Corrales

引用次数: 0

Trans-signaling through the agonistic sIL-6R and an imbalanced inflammatory response are associated with increased susceptibility to Graves’ disease 通过激动性sIL-6R的反式信号传导和不平衡的炎症反应与格雷夫斯病易感性增加有关

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-07-30 DOI: 10.1016/j.endien.2025.501598

Zulvikar Syambani Ulhaq , Zulkarnain Zulkarnain , Lola Ayu Istifiani , Syafrizal Aji Pamungkas , Susiati , Djoko Wahono Soeatmadji , Aulanni’am Aulanni’am

Background

Excessive inflammatory cytokines are known to impact immune response and autoimmunity. In this study, we quantified the level of interleukin (IL)-6, soluble IL-6 receptor (sIL-6R), glycoprotein 130 (sgp130) and IL-10 to determine their involvement in the pathogenesis of Graves’ disease (GD), in addition to the assessment serum cytokines IL-6, sIL-6R, sgp130, and IL-10 performance as biomarkers for the diagnosis of GD.

Methods

A total of 20 patients with GD and 21 healthy individuals from the Indonesian population were enrolled. The serum concentrations of the selected cytokines were quantified using the ELISA method. Thyroid-stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3), and TSH receptor antibody (TSHR-Ab) were also evaluated. Comparative analysis was performed in addition to the assessment of the diagnostic performance of cytokines using receiver-operating-curve (ROC) analysis. Pearson's correlation coefficient was used to assess the relationship between 2 quantitative variables.

Results

Patients with GD had a higher IL-6, sIL-6R, and IL-6/IL-10 ratio but a lower sgp130/sIL-6R/IL-6 ratio vs controls. The ROC curve analysis showed that the sgp130/sIL-6R/IL-6 ratio exhibited better performance than IL-6, sIL-6R, and IL-6/IL-10 ratio in diagnosing GD. In addition, serum levels of IL-6, sIL-6, and IL-10 were associated with thyroid parameters, including TSHR-antibody (Ab) levels.

Conclusion

IL-6 trans-signaling and imbalance of inflammatory response could be prominent factors in the pathogenesis of GD.

背景炎性细胞因子过多会影响免疫反应和自身免疫。在本研究中，我们量化了白细胞介素(IL)-6、可溶性IL-6受体（sIL-6R）、糖蛋白130 （sgp130）和IL-10的水平，以确定它们在Graves病（GD）发病中的作用，并评估了血清细胞因子IL-6、sIL-6R、sgp130和IL-10的表现，作为GD诊断的生物标志物。方法从印度尼西亚人群中选取20例GD患者和21例健康人作为研究对象。采用ELISA法定量所选细胞因子的血清浓度。同时检测促甲状腺激素（TSH）、游离甲状腺素（FT4）、游离三碘甲状腺原氨酸（FT3）和TSH受体抗体（TSHR-Ab）。采用受体-工作曲线（ROC）分析对细胞因子的诊断效能进行评价，并进行比较分析。采用Pearson相关系数评价两个定量变量之间的关系。结果GD患者IL-6、sIL-6R和IL-6/IL-10比值高于对照组，但sgp130/sIL-6R/IL-6比值低于对照组。ROC曲线分析显示，sgp130/sIL-6R/IL-6比值在诊断GD方面优于IL-6、sIL-6R和IL-6/IL-10比值。此外，血清IL-6、sIL-6和IL-10水平与甲状腺参数相关，包括tshr抗体（Ab）水平。结论il -6反式信号和炎症反应失衡可能是GD发病的重要因素。

{"title":"Trans-signaling through the agonistic sIL-6R and an imbalanced inflammatory response are associated with increased susceptibility to Graves’ disease","authors":"Zulvikar Syambani Ulhaq , Zulkarnain Zulkarnain , Lola Ayu Istifiani , Syafrizal Aji Pamungkas , Susiati , Djoko Wahono Soeatmadji , Aulanni’am Aulanni’am","doi":"10.1016/j.endien.2025.501598","DOIUrl":"10.1016/j.endien.2025.501598","url":null,"abstract":"<div><h3>Background</h3><div>Excessive inflammatory cytokines are known to impact immune response and autoimmunity. In this study, we quantified the level of interleukin (IL)-6, soluble IL-6 receptor (sIL-6R), glycoprotein 130 (sgp130) and IL-10 to determine their involvement in the pathogenesis of Graves’ disease (GD), in addition to the assessment serum cytokines IL-6, sIL-6R, sgp130, and IL-10 performance as biomarkers for the diagnosis of GD.</div></div><div><h3>Methods</h3><div>A total of 20 patients with GD and 21 healthy individuals from the Indonesian population were enrolled. The serum concentrations of the selected cytokines were quantified using the ELISA method. Thyroid-stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3), and TSH receptor antibody (TSHR-Ab) were also evaluated. Comparative analysis was performed in addition to the assessment of the diagnostic performance of cytokines using receiver-operating-curve (ROC) analysis. Pearson's correlation coefficient was used to assess the relationship between 2 quantitative variables.</div></div><div><h3>Results</h3><div>Patients with GD had a higher IL-6, sIL-6R, and IL-6/IL-10 ratio but a lower sgp130/sIL-6R/IL-6 ratio vs controls. The ROC curve analysis showed that the sgp130/sIL-6R/IL-6 ratio exhibited better performance than IL-6, sIL-6R, and IL-6/IL-10 ratio in diagnosing GD. In addition, serum levels of IL-6, sIL-6, and IL-10 were associated with thyroid parameters, including TSHR-antibody (Ab) levels.</div></div><div><h3>Conclusion</h3><div>IL-6 trans-signaling and imbalance of inflammatory response could be prominent factors in the pathogenesis of GD.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 7","pages":"Article 501598"},"PeriodicalIF":1.8,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144722266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Broadening perspectives on hypoglycemia diagnosis in non-diabetic patients 拓宽非糖尿病患者低血糖诊断的视角

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-07-30 DOI: 10.1016/j.endien.2025.501599

Beatriz Rodríguez Jiménez , Ignacio Jiménez Varo , Fernando-Francisco Ortega Ortega , Mariola Méndez Muros , Félix Sánchez Fernández , María Asunción Martínez-Brocca

A 51-year-old man with a past medical history of chronic alcoholism was admitted for a planned fasting test due to suspected hypoglycemia. Despite previous evaluations by cardiology and neurology revealing no evident etiology, his syncopal episodes were suspected be associated with inconsistent hypoglycemic episodes. During his hospital admission, the patient experienced several syncopal episodes with associated seizures, which, at the time, were not related to hypoglycemia. This led to further investigation, including the exclusion of other causes, such as a possible autonomic dysfunction. Neurology consequently expanded the assessment, identifying subtle signs of mild parkinsonism and symptoms suggestive of a REM sleep disorder, which shifted the diagnostic suspicion.

This case underscores the importance of considering other clinical conditions when evaluating hypoglycemia, especially when classic symptoms are absent or inconsistently presented, and an endocrinological origin has been ruled out.

51岁男性，既往有慢性酒精中毒病史，因怀疑低血糖而入院接受空腹检查。尽管先前的心脏病学和神经学评估显示没有明确的病因，但他的晕厥发作被怀疑与不一致的低血糖发作有关。在住院期间，患者经历了几次晕厥发作并伴有癫痫发作，当时与低血糖无关。这导致进一步的调查，包括排除其他原因，如可能的自主神经功能障碍。神经学随后扩大了评估范围，发现了轻度帕金森症的细微迹象和暗示快速眼动睡眠障碍的症状，这改变了诊断的怀疑。本病例强调了在评估低血糖时考虑其他临床条件的重要性，特别是当经典症状不存在或不一致出现时，并已排除内分泌起源。

{"title":"Broadening perspectives on hypoglycemia diagnosis in non-diabetic patients","authors":"Beatriz Rodríguez Jiménez , Ignacio Jiménez Varo , Fernando-Francisco Ortega Ortega , Mariola Méndez Muros , Félix Sánchez Fernández , María Asunción Martínez-Brocca","doi":"10.1016/j.endien.2025.501599","DOIUrl":"10.1016/j.endien.2025.501599","url":null,"abstract":"<div><div>A 51-year-old man with a past medical history of chronic alcoholism was admitted for a planned fasting test due to suspected hypoglycemia. Despite previous evaluations by cardiology and neurology revealing no evident etiology, his syncopal episodes were suspected be associated with inconsistent hypoglycemic episodes. During his hospital admission, the patient experienced several syncopal episodes with associated seizures, which, at the time, were not related to hypoglycemia. This led to further investigation, including the exclusion of other causes, such as a possible autonomic dysfunction. Neurology consequently expanded the assessment, identifying subtle signs of mild parkinsonism and symptoms suggestive of a REM sleep disorder, which shifted the diagnostic suspicion.</div><div>This case underscores the importance of considering other clinical conditions when evaluating hypoglycemia, especially when classic symptoms are absent or inconsistently presented, and an endocrinological origin has been ruled out.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 7","pages":"Article 501599"},"PeriodicalIF":1.8,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144722269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical, diagnostic and therapeutic aspects of Mauriac syndrome, a complication of type 1 diabetes mellitus: A systematic review 1型糖尿病并发症莫里亚克综合征的临床、诊断和治疗：系统综述

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-07-30 DOI: 10.1016/j.endien.2025.501611

André Saad Cleto, João Matheus Schirlo, Mayara Beltrame, Victor Hugo Oliveira Gomes, Janete Machozeki, Camila Marinelli Martins

This systematic review aimed to present the main clinical, diagnostic and therapeutic aspects of Mauriac syndrome, which is a rare syndrome that mainly affects children and adolescents with uncontrolled type 1 diabetes mellitus. This review was carried out in accordance with PRISMA and registered in PROSPERO (CRD42024531249). The following databases were used in our search: PubMed, Lilacs and Scielo, on 04/02/2024. Studies that presented any data on patients with Mauriac syndrome were included, however, review studies, letters to the editor and animal studies were excluded. The risk of bias was assessed using a specific method for case reports. To analyze the results, the general, clinical, diagnostic and therapeutic characteristics were analyzed using a qualitative analysis. A total of 24 studies were included, 18 case reports and 6 case series. The patients’ mean age was 16.26 years, and the mean glycated hemoglobin was 12.93%. The main signs and symptoms reported were hepatomegaly (88%), short stature (52%), cushingoid features (35%) and abdominal discomfort (26%). The means of AST, ALT, GGT, alkaline phosphatase, total cholesterol, triglycerides and lactate were above the reference value. Some studies used abdominal ultrasound (US), abdominal computed tomography (CT) or liver biopsy to make the diagnosis. CT and US showed hepatomegaly, while liver biopsies showed glycogen accumulation in hepatocytes. Treatment in most studies was based on improving blood glucose levels and diet. Therefore, Mauriac syndrome has diverse symptoms. Lab test and imaging modalities can be useful to establish diagnosis.

本系统综述旨在介绍毛里亚克综合征的主要临床、诊断和治疗方面，这是一种罕见的综合征，主要发生在儿童和青少年未控制的1型糖尿病。该审查按照PRISMA进行，并在PROSPERO注册（CRD42024531249）。我们在2024年2月4日的搜索中使用了以下数据库：PubMed， Lilacs和Scielo。提供毛里亚克综合征患者数据的研究被包括在内，然而，综述研究、给编辑的信件和动物研究被排除在外。使用病例报告的特定方法评估偏倚风险。为了分析结果，采用定性分析方法分析一般、临床、诊断和治疗特点。共纳入24项研究，18例病例报告和6例病例系列。患者平均年龄16.26岁，平均糖化血红蛋白为12.93%。报告的主要体征和症状为肝肿大（88%）、身材矮小（52%）、库申样特征（35%）和腹部不适（26%）。AST、ALT、GGT、碱性磷酸酶、总胆固醇、甘油三酯、乳酸均高于参考值。一些研究使用腹部超声（US）、腹部计算机断层扫描（CT）或肝脏活检进行诊断。CT和US显示肝肿大，肝活检显示肝细胞糖原积聚。在大多数研究中，治疗是基于改善血糖水平和饮食。因此，毛里亚克综合征有多种症状。实验室检查和影像学检查有助于诊断。

{"title":"Clinical, diagnostic and therapeutic aspects of Mauriac syndrome, a complication of type 1 diabetes mellitus: A systematic review","authors":"André Saad Cleto, João Matheus Schirlo, Mayara Beltrame, Victor Hugo Oliveira Gomes, Janete Machozeki, Camila Marinelli Martins","doi":"10.1016/j.endien.2025.501611","DOIUrl":"10.1016/j.endien.2025.501611","url":null,"abstract":"<div><div>This systematic review aimed to present the main clinical, diagnostic and therapeutic aspects of Mauriac syndrome, which is a rare syndrome that mainly affects children and adolescents with uncontrolled type 1 diabetes mellitus. This review was carried out in accordance with PRISMA and registered in PROSPERO (CRD42024531249). The following databases were used in our search: PubMed, Lilacs and Scielo, on 04/02/2024. Studies that presented any data on patients with Mauriac syndrome were included, however, review studies, letters to the editor and animal studies were excluded. The risk of bias was assessed using a specific method for case reports. To analyze the results, the general, clinical, diagnostic and therapeutic characteristics were analyzed using a qualitative analysis. A total of 24 studies were included, 18 case reports and 6 case series. The patients’ mean age was 16.26 years, and the mean glycated hemoglobin was 12.93%. The main signs and symptoms reported were hepatomegaly (88%), short stature (52%), cushingoid features (35%) and abdominal discomfort (26%). The means of AST, ALT, GGT, alkaline phosphatase, total cholesterol, triglycerides and lactate were above the reference value. Some studies used abdominal ultrasound (US), abdominal computed tomography (CT) or liver biopsy to make the diagnosis. CT and US showed hepatomegaly, while liver biopsies showed glycogen accumulation in hepatocytes. Treatment in most studies was based on improving blood glucose levels and diet. Therefore, Mauriac syndrome has diverse symptoms. Lab test and imaging modalities can be useful to establish diagnosis.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 7","pages":"Article 501611"},"PeriodicalIF":1.8,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144722267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estimation of the incidence and prevalence of type 1 diabetes mellitus in children under 15 years of age in Spain 西班牙15岁以下儿童1型糖尿病发病率和患病率的估计

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-07-10 DOI: 10.1016/j.endien.2025.501591

Santiago Conde Barreiro , Beatriz González Pelegrín , Bárbara Quevedo Beneyto , Cristina Feja Solana , Carmen Malo Aznar , Gemma Rojo-Martínez , Edelmiro Menéndez Torre , Fernando Gómez Peralta

Introduction

Epidemiological studies on type 1 diabetes mellitus (DM1) have been developed in almost all the Spanish geography, but no registry currently provides national incidence and prevalence figures. This study aims to estimate the incidence of DM1 in children under 15 years of age in Spain based on the available studies, and to know the prevalence of diabetes in children under 15 years of age based from the data collected in the Primary Care Clinical Database (BDCAP).

Material and methods

Bibliographic review of publications and communications that provided data up to December 2020. Estimation of the average incidence in Spain, based on data from each autonomous community. Estimation of the prevalence of DM1 in children under 15 years of age according to BDCAP.

Results

The reported incidences varied from 7.9 cases/100,000 population per year (c/10⁵ppy) in the Balearic Islands to 30.48 c/10⁵ppy in Gran Canaria. Diagnosis in diabetic ketoacidosis (DKA) is found in approximately one third of cases (21-43.7%). The average incidence of DM1 in children under 15 years of age in Spain would be 20.54 c/10⁵ppy, with about 1,398 new cases per year. BDCAP records 12,346 cases of diabetes in children under 15 years of age, with a prevalence of 1.96 cases/1,000 population.

Conclusions

There are studies of DM1 incidence in almost all Spanish communities. The incidence of DM1 in children under 15 years of age in Spain is very high according to the WHO classification (> 20 c/10⁵ppy). The proportion of cases diagnosed with CAD is high, suggesting that programs to improve the early diagnosis of DM1 are still needed.

西班牙几乎所有地区都开展了1型糖尿病（DM1）的流行病学研究，但目前没有提供全国发病率和患病率数据的登记处。本研究旨在根据现有研究估计西班牙15岁以下儿童DM1的发病率，并根据初级保健临床数据库（BDCAP）收集的数据了解15岁以下儿童糖尿病的患病率。材料和方法：对截至2020年12月提供数据的出版物和通讯进行书目审查。根据每个自治区的数据估计西班牙的平均发病率。根据BDCAP估计15岁以下儿童DM1患病率。结果：报告的发病率从巴利阿里群岛的每年7.9例/10万人（c/105ppy）到大加那利岛的30.48例c/105ppy不等。糖尿病酮症酸中毒（DKA）的诊断在大约三分之一的病例中发现（21-43.7%）。西班牙15岁以下儿童DM1的平均发病率为20.54 c/105，每年约有1398例新病例。BDCAP记录了15岁以下儿童糖尿病病例12,346例，患病率为1.96例/1,000人。结论：在几乎所有西班牙社区都有DM1发病率的研究。根据世卫组织的分类，西班牙15岁以下儿童DM1的发病率非常高（bbb20c / 105py）。诊断为CAD的病例比例很高，这表明仍然需要提高DM1的早期诊断。

{"title":"Estimation of the incidence and prevalence of type 1 diabetes mellitus in children under 15 years of age in Spain","authors":"Santiago Conde Barreiro , Beatriz González Pelegrín , Bárbara Quevedo Beneyto , Cristina Feja Solana , Carmen Malo Aznar , Gemma Rojo-Martínez , Edelmiro Menéndez Torre , Fernando Gómez Peralta","doi":"10.1016/j.endien.2025.501591","DOIUrl":"10.1016/j.endien.2025.501591","url":null,"abstract":"<div><h3>Introduction</h3><div>Epidemiological studies on type 1 diabetes mellitus (DM1) have been developed in almost all the Spanish geography, but no registry currently provides national incidence and prevalence figures. This study aims to estimate the incidence of DM1 in children under 15 years of age in Spain based on the available studies, and to know the prevalence of diabetes in children under 15 years of age based from the data collected in the Primary Care Clinical Database (BDCAP).</div></div><div><h3>Material and methods</h3><div>Bibliographic review of publications and communications that provided data up to December 2020. Estimation of the average incidence in Spain, based on data from each autonomous community. Estimation of the prevalence of DM1 in children under 15 years of age according to BDCAP.</div></div><div><h3>Results</h3><div>The reported incidences varied from 7.9 cases/100,000 population per year (c/10<sup>5</sup>ppy) in the Balearic Islands to 30.48 c/10<sup>5</sup>ppy in Gran Canaria. Diagnosis in diabetic ketoacidosis (DKA) is found in approximately one third of cases (21-43.7%). The average incidence of DM1 in children under 15 years of age in Spain would be 20.54 c/10<sup>5</sup>ppy, with about 1,398 new cases per year. BDCAP records 12,346 cases of diabetes in children under 15 years of age, with a prevalence of 1.96 cases/1,000 population.</div></div><div><h3>Conclusions</h3><div>There are studies of DM1 incidence in almost all Spanish communities. The incidence of DM1 in children under 15 years of age in Spain is very high according to the WHO classification (> 20 c/10<sup>5</sup>ppy). The proportion of cases diagnosed with CAD is high, suggesting that programs to improve the early diagnosis of DM1 are still needed.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 7","pages":"Article 501591"},"PeriodicalIF":1.8,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144620860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hand dynamometry: Does the device used for measurement matter? 手测力：测量所用的装置重要吗？

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-07-09 DOI: 10.1016/j.endien.2025.501575

Diana García Sastre, Begoña Pintor de la Maza, María López Melgar, María D. Ballesteros Pomar

Introduction

Handgrip dynamometers measure muscle strength through the grip strength of the dominant hand. The purpose of this study is to compare the Dynx, Saehan, and Smedlay dynamometers with the Jamar dynamometer (gold standard) by evaluating the correlation and concordance of their measurements to determine if it is indifferent to use different dynamometers.

Material and methods

Cross-sectional study conducted between 2020 and 2021.

We evaluated a group of patients (GP) from the Endocrinology and Nutrition consultations and a control group (CG) of health personnel.

Dominant hand grip strength was measured with four different dynamometers Jamar, Dynx, Saehan and Smedlay, in random order. Statistical analysis was performed with SPSS using Student's t-test, intraclass correlation coefficient (ICC), and Bland-Altman plots.

Results

A total of 124 subjects were included; 91 GP (60.4% women), mean age 54.9 (SD14.2) years. ICC showed the best correlation for Saehan in GP (0.977 p < 0.001) and in GC (0.960 p < 0.001). Dynx correlated better in GP than in GC (0.967 vs. 0.900, p < 0.001) and Smedlay had the worst correlation in GC (0.812 p < 0.001). The dynamometer with the lowest bias (-0.39, SD 3.11) and better limits of agreement (LOA) in both groups (GP -0.39, GC -0.51) was the Saehan

Conclusion

Despite good measurement correlation, there is bias and insufficient agreement between different dynamometers, so they should not be used interchangeably.

介绍：握力计通过优势手的握力来测量肌肉力量。本研究的目的是比较Dynx， Saehan和Smedlay测功机与Jamar测功机（金标准），通过评估其测量的相关性和一致性来确定使用不同的测功机是否无关。材料和方法：在2020 - 2021年间进行横断面研究。我们评估了一组来自内分泌和营养咨询的患者（GP）和一组卫生人员的对照组（CG）。用四种不同的测力仪（Jamar, Dynx， Saehan和Smedlay）按随机顺序测量优势手握力。统计分析采用SPSS进行，采用学生t检验、类内相关系数（ICC）和Bland-Altman图。结果：共纳入124名受试者；91名GP（60.4%为女性），平均年龄54.9岁（SD14.2）岁。ICC与GP相关性最佳（0.977 p）

{"title":"Hand dynamometry: Does the device used for measurement matter?","authors":"Diana García Sastre, Begoña Pintor de la Maza, María López Melgar, María D. Ballesteros Pomar","doi":"10.1016/j.endien.2025.501575","DOIUrl":"10.1016/j.endien.2025.501575","url":null,"abstract":"<div><h3>Introduction</h3><div>Handgrip dynamometers measure muscle strength through the grip strength of the dominant hand. The purpose of this study is to compare the Dynx, Saehan, and Smedlay dynamometers with the Jamar dynamometer (gold standard) by evaluating the correlation and concordance of their measurements to determine if it is indifferent to use different dynamometers.</div></div><div><h3>Material and methods</h3><div>Cross-sectional study conducted between 2020 and 2021.</div><div>We evaluated a group of patients (GP) from the Endocrinology and Nutrition consultations and a control group (CG) of health personnel.</div><div>Dominant hand grip strength was measured with four different dynamometers Jamar, Dynx, Saehan and Smedlay, in random order. Statistical analysis was performed with SPSS using Student's t-test, intraclass correlation coefficient (ICC), and Bland-Altman plots.</div></div><div><h3>Results</h3><div>A total of 124 subjects were included; 91 GP (60.4% women), mean age 54.9 (SD14.2) years. ICC showed the best correlation for Saehan in GP (0.977 p < 0.001) and in GC (0.960 p < 0.001). Dynx correlated better in GP than in GC (0.967 vs. 0.900, p < 0.001) and Smedlay had the worst correlation in GC (0.812 p < 0.001). The dynamometer with the lowest bias (-0.39, SD 3.11) and better limits of agreement (LOA) in both groups (GP -0.39, GC -0.51) was the Saehan</div></div><div><h3>Conclusion</h3><div>Despite good measurement correlation, there is bias and insufficient agreement between different dynamometers, so they should not be used interchangeably.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 7","pages":"Article 501575"},"PeriodicalIF":1.8,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neglect in the parental care of children and adolescents with type 1 diabetes. Predictors 父母对1型糖尿病儿童和青少年的忽视。预测因子。

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-07-09 DOI: 10.1016/j.endien.2025.501581

Emilio García-García , Juan Gil-Arrones , Antonio J. Molina-Facio , Elena Digón-Fernández , Manuel Sobrino-Toro

引用次数: 0

Transient syndrome of inappropriate antidiuresis due to intracranial hematoma in a patient with partial antidiuretic hormone deficiency and Steinert’s dystrophy 部分抗利尿激素缺乏伴斯泰纳特营养不良患者颅内血肿所致不适当抗利尿的短暂综合征。

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-07-08 DOI: 10.1016/j.endien.2025.501592

Guillermo Ropero-Luis , Viyey Kishore Doulatram-Gamgaram

引用次数: 0

Advanced diagnostic imaging techniques in pituitary pathology 垂体病理的先进诊断成像技术。

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-07-08 DOI: 10.1016/j.endien.2025.501610

Beatriz Brea Álvarez

引用次数: 0

Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study 从每周一次的杜拉鲁肽转换为每周一次的西马鲁肽的有效性和安全性的实际评估：SEMA-SWITCH研究。

IF 1.8 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrinologia Diabetes Y Nutricion

Pub Date : 2025-06-01 DOI: 10.1016/j.endien.2025.501574

Felipe Pardo Lozano , Arantxa Rubio Marcos , Rosa Casañ Fernández , Amparo Bartual Rodrigo , Sergio Martínez-Hervás , Francisco Javier Ampudia-Blasco

Introduction

Dulaglutide and semaglutide are once-weekly administered GLP-1 receptor agonists (GLP-1 RAs) indicated for the treatment of hyperglycemia in individuals with type 2 diabetes mellitus (T2DM) and obesity (BMI ≥ 30 kg/m²).

Objective

To evaluate the efficacy and safety of switching from subcutaneous (SC) dulaglutide to SC semaglutide, in real-world conditions.

Materials and methods

A total of 123 individuals with T2DM on SC dulaglutide, either as monotherapy or with other antihyperglycemic drugs, who switched to SC semaglutide were included. This switch was motivated by insufficient reduction in glycated hemoglobin (HbA1C), the need for greater weight loss, or gastrointestinal intolerance associated with dulaglutide. Changes with semaglutide in HbA1C and weight at 6, 12, 18, and 24 mo, as well as any changes in associated adverse effects. Data are expressed as mean ± standard deviation.

Results

Previous treatment with dulaglutide (duration 16.9 ± 13.8 mo) reduced HbA1c by 0.38% (p = 0.003 vs. baseline) and weight by −1.3 kg (p = 0.003 vs. baseline). After switching to semaglutide, an additional reduction in HbA1C levels was observed at 6, 12, 18, and 24 mo (−0.43%, p = 0.000; −0.54%, p = 0.000; −0.38%, p = 0.021; −0.12%, p = 0.622, respectively) and in weight at 6, 12, 18, and 24 mo (−2.7 kg, p = 0.000; −3.7 kg, p = 0.000; −5.4 kg, p = 0.001; −4.2 kg, p = 0.000, respectively) With no significant differences in the frequency of adverse effects after switching to semaglutide.

Conclusions

In real-world conditions, switching dulaglutide to semaglutide in obese patients with T2DM is associated with an additional reduction in HbA1C and weight, without notable changes in the frequency of adverse effects.

Dulaglutide和semaglutide是每周一次的GLP-1受体激动剂（GLP-1 RAs），用于治疗2型糖尿病（T2DM）和肥胖（BMI ≥ 30 kg/m2）患者的高血糖。目的：评价在现实条件下，从皮下（SC）杜拉鲁肽转换为皮下（SC） semaglutide的有效性和安全性。材料和方法：共有123例T2DM患者接受SC西马鲁肽单药治疗或与其他降糖药物联合治疗，转而使用SC西马鲁肽。这种转变的动机是糖化血红蛋白（HbA1C）降低不足，需要更大程度的减肥，或杜拉鲁肽相关的胃肠道不耐受。在6、12、18和24 mo时使用西马鲁肽的HbA1C和体重变化，以及相关不良反应的任何变化。数据表示为平均值 ± 标准差。结果：先前的dulaglutide治疗（持续时间16.9 ± 13.8 mo）使HbA1c降低0.38% （p = 0.003与基线相比），体重降低-1.3 kg （p = 0.003与基线相比）。改用semaglutide后，在6、12、18和24个月时观察到HbA1C水平的进一步降低 mo (-0.43%, p = 0.000；-0.54%, p = 0.000;-0.38%, p = 0.021;-0.12%, p = 0.622)，体重在6、12、18和24 月(-2.7 kg, p = 0.000； 公斤-3.7,p = 0.000; 公斤-5.4,p = 0.001;-4.2 kg, p = 0.000)改用西马鲁肽后不良反应发生频率无显著差异。结论：在现实条件下，肥胖T2DM患者将dulaglutide转换为semaglutide与HbA1C和体重的额外降低相关，而不良反应的频率没有显着变化。

{"title":"Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study","authors":"Felipe Pardo Lozano , Arantxa Rubio Marcos , Rosa Casañ Fernández , Amparo Bartual Rodrigo , Sergio Martínez-Hervás , Francisco Javier Ampudia-Blasco","doi":"10.1016/j.endien.2025.501574","DOIUrl":"10.1016/j.endien.2025.501574","url":null,"abstract":"<div><h3>Introduction</h3><div>Dulaglutide and semaglutide are once-weekly administered GLP-1 receptor agonists (GLP-1 RAs) indicated for the treatment of hyperglycemia in individuals with type 2 diabetes mellitus (T2DM) and obesity (BMI ≥ 30 kg/m<sup>2</sup>).</div></div><div><h3>Objective</h3><div>To evaluate the efficacy and safety of switching from subcutaneous (SC) dulaglutide to SC semaglutide, in real-world conditions.</div></div><div><h3>Materials and methods</h3><div>A total of 123 individuals with T2DM on SC dulaglutide, either as monotherapy or with other antihyperglycemic drugs, who switched to SC semaglutide were included. This switch was motivated by insufficient reduction in glycated hemoglobin (HbA1C), the need for greater weight loss, or gastrointestinal intolerance associated with dulaglutide. Changes with semaglutide in HbA1C and weight at 6, 12, 18, and 24 mo, as well as any changes in associated adverse effects. Data are expressed as mean ± standard deviation.</div></div><div><h3>Results</h3><div>Previous treatment with dulaglutide (duration 16.9 ± 13.8 mo) reduced HbA1c by 0.38% (p = 0.003 vs. baseline) and weight by −1.3 kg (p = 0.003 vs. baseline). After switching to semaglutide, an additional reduction in HbA1C levels was observed at 6, 12, 18, and 24 mo (−0.43%, p = 0.000; −0.54%, p = 0.000; −0.38%, p = 0.021; −0.12%, p = 0.622, respectively) and in weight at 6, 12, 18, and 24 mo (−2.7 kg, p = 0.000; −3.7 kg, p = 0.000; −5.4 kg, p = 0.001; −4.2 kg, p = 0.000, respectively) With no significant differences in the frequency of adverse effects after switching to semaglutide.</div></div><div><h3>Conclusions</h3><div>In real-world conditions, switching dulaglutide to semaglutide in obese patients with T2DM is associated with an additional reduction in HbA1C and weight, without notable changes in the frequency of adverse effects.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"72 6","pages":"Article 501574"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144227264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Endocrinologia Diabetes Y Nutricion

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀